Clinical Trials
46 trialsNCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05797168 2026-06-03
FONTANA
AstraZeneca
Phase 1/2 Recruiting
NCT05739981 2026-06-02
MRD
Imunon
Phase 1/2 Recruiting
NCT04956640 2026-05-29
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT04938583 2026-04-06
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Active not recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT06840002 2025-09-30
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed
NCT06990516 2025-05-25
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT02098343 2025-03-17
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Aprea Therapeutics
Phase 1/2 Completed
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT04493619 2024-11-04
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
Phase 1/2 Terminated
NCT03287271 2024-08-12
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
University of California, San Diego
Phase 1/2 Recruiting
NCT03126812 2024-05-29
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT04814875 2024-02-14
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
Phase 1/2 Terminated
NCT01402271 2023-12-11
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT00788125 2023-07-14
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase 1/2 Terminated
NCT01133756 2023-06-22
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Eisai Inc.
Phase 1/2 Terminated
NCT01618136 2023-06-18
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated
NCT03029598 2022-07-26
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1/2 Completed
NCT03394885 2021-08-12
AdORN
Duke University
Phase 1/2 Completed
NCT01690468 2020-09-24
PTX-200 and Carboplatin in Ovarian Cancer
Prescient Therapeutics, Ltd.
Phase 1/2 Terminated
NCT00910000 2018-09-10
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00228319 2018-06-19
Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants
University of Kansas Medical Center
Phase 1/2 Completed
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown
NCT01188876 2018-01-19
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT00562185 2017-11-20
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00002558 2016-05-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00423852 2016-05-18
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01637532 2016-01-26
PITCH
Leiden University Medical Center
Phase 1/2 Completed
NCT01624493 2015-12-23
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT00421889 2015-07-28
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Phase 1/2 Completed
NCT00003064 2014-01-06
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00886717 2013-08-02
Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003136 2013-02-11
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
University of Chicago
Phase 1/2 Completed
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00032162 2012-05-31
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
AGO Study Group
Phase 1/2 Completed
NCT00750386 2011-05-23
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT00316407 2011-02-18
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Swedish Medical Center
Phase 1/2 Completed
NCT00002508 2010-10-01
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Temple University
Phase 1/2 Completed
NCT00217529 2010-09-21
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed